AXQ Capital’s Capricor Therapeutics CAPR Stock Holding History

AXQ Capital’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-8,253	Closed	-$251K	–	1029
2026 Q1	$251K	Buy	+8,253	New	+$220K	0.03%	655

Other funds holding CAPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AXQ Capital's CAPR Position: Q2 2026 in Review

AXQ Capital sold out of Capricor Therapeutics (CAPR) in Q2 2026, closing a stake of 8,253 shares — an estimated $251K sold.

AXQ Capital first reported a position in CAPR in Q1 2026 and held it in 1 quarter. The position peaked at $251K in Q1 2026. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

AXQ Capital reported no remaining Capricor Therapeutics position as of Q2 2026 after selling out during the quarter.
AXQ Capital sold 8,253 Capricor Therapeutics shares in Q2 2026, an estimated $251K.
AXQ Capital first reported a position in Capricor Therapeutics in Q1 2026 and held it in 1 quarter.
AXQ Capital's Capricor Therapeutics position peaked at $251K in Q1 2026.
170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.